{"title": "Computational Analysis for the Rational Design of Anti-Amyloid Beta  (ABeta) Antibodies", "tag": "q-bio", "abstract": " Alzheimer's Disease (AD) is a neurodegenerative disorder that lacks effective treatment options. Anti-amyloid beta (ABeta) antibodies are the leading drug candidates to treat AD, but the results of clinical trials have been disappointing. Introducing rational mutations into anti-ABeta antibodies to increase their effectiveness is a way forward, but the path to take is unclear. In this study, we demonstrate the use of computational fragment-based docking and MMPBSA binding free energy calculations in the analysis of anti-ABeta antibodies for rational drug design efforts. Our fragment-based docking method successfully predicted the emergence of the common EFRH epitope, MD simulations coupled with MMPBSA binding free energy calculations were used to analyze scenarios described in prior studies, and we introduced rational mutations into PFA1 to improve its calculated binding affinity towards the pE3-ABeta3-8 form of ABeta. Two out of four proposed mutations stabilized binding. Our study demonstrates that a computational approach may lead to an improved drug candidate for AD in the future. ", "text": "options. anti-amyloid beta antibodies leading drug candidates treat results clinical trials disappointing. introducing rational mutations anti-ağ›½ğ›½ binding free energy calculations analysis anti-ağ›½ğ›½ antibodies rational drug design amyloid beta peptides appearance intracellular neurofibrillary tangles plaques brain responsible cognitive decline observed patients. suggests clearing plaques brain would help inhibit reverse progression treatment immunotherapy-. several active passive anti-ağ›½ğ›½ immunotherapies target species brain advanced clinical trials results thus disappointing. vaccine targeted full-size peptide advanced terminal ağ›½ğ›½âˆ’ sequence used specific cell epitopes ağ›½ğ›½âˆ’ used specific cell epitopes. choice epitope crucial effect ability binding aggregated forms central c-terminal epitopes able bind antibody monomeric perhaps small oligomeric forms central initially anti-ağ›½ğ›½ monoclonal antibodies advanced clinical trials targeting distinct epitopes/species ağ›½ğ›½. bapineuzumab primarily targets insoluble amyloid plaques hydrophilic n-terminal epitope ağ›½ğ›½âˆ’. initial results looked promising phase solanezumab targets soluble monomeric peptides hydrophobic central ağ›½ğ›½âˆ’ effective treatment. example normally rare n-terminal truncated variants found much higher concentrations stable neurotoxic aggregates pe-ağ›½ğ›½ form ağ›½ğ›½- pe-ağ›½ğ›½ become target antibody development-. epitope associated single species might enough antibody treat epitopes species currently clinical trials. gantenerumab binds nanomolar affinity several species recognizes epitopes within n-terminal crenezumab despite generated immunization n-terminal ağ›½ğ›½âˆ’ epitope- shown bind monomeric oligomeric forms central epitope emphasized studies crenezumab co-crystal structure crenezumab recently obtained bound peptide containing epitopes accounting binding fibril oligomeric forms ağ›½ğ›½. study taken computational approach explore anti-ağ›½ğ›½ antibody bind epitopes antigen-combining site questions literature including residues ağ›½ğ›½âˆ’ important initial binding event anchors given antibody structure? might antibodies binding affinity polymorphic form towards anti-ağ›½ğ›½ antibody? method probe antigen-combining site various anti-ağ›½ğ›½ antibodies using single amino using available crystal structures gantenerumab crenezumab bound short terminal central epitopes recognized antibody. third question built study bound ağ›½ğ›½âˆ’ pe-ağ›½ğ›½âˆ’ carried previously gardberg improving binding affinity pe-ağ›½ğ›½âˆ’ accessible test case given sequence charge characteristics binding pose pe-ağ›½ğ›½âˆ’ computational docking amino acid residues anti-ağœ·ğœ· antibodies initial binding characteristics antigen-combining site various anti-ağ›½ğ›½ antibodies. amino acids individually docked antibody comprising full computational docking amino acid residues anti-ağœ·ğœ· antibodies anchoring peptide anti-amyloid antibody carried unbiased fragmentağ›½ğ›½âˆ’ sequence. minimize conformational effects polypeptide ligand chose bound antigen-combining sites anti-ağ›½ğ›½ antibody structures. table region amino acid residues ranked appear region. furthermore amino acid residues ranked terminal daefrh epitope bind anti-ağ›½ğ›½ antibodies. combining site residue across different anti-ağ›½ğ›½ antibodies. consider time appear region appear region. presence aromatic binding pocket antibody important binding ağ›½ğ›½. phenylalanine several anti-ağ›½ğ›½ antibody crystallographers addition prominent epitopes n-terminal daefrh epitope central klvffaed epitope correspond locations sequence phenylalanine appears. leading candidate important anchor residue initial binding epitopes importance phenylalanine stable binding ağœ·ğœ·âˆ’ test importance phenylalanine peptide-antibody binding studied ağ›½ğ›½âˆ’ several ağ›½ğ›½âˆ’ sequence variants bound pfa. demonstrated analysis gantenerumab crenezumab binding multiple epitopes binding peptides anti-amyloid antibodies also examined antigen-combining might bind n-terminal central epitopes peptides. first simulations peptides observed crystal structures afterwards generated homology models containing prominent epitope peptide modeled forward reverse orientations across antigencombining site location phenylalanine residues epitopes used source strong binding affinity n-terminal peptide seems apparent negatively charged aspartate glutamate residues appear n-terminal comparing original n-terminal peptide binding pose figure binding pose transposed central peptide figure electrostatic contacts lost central peptide bound n-terminal peptide bound drops central peptide bound percent occupancy n-terminal peptide bound actually increased central peptide bound. however worth noting appears competing occupancy central peptide bound. figures much less stable binding free energy kcal/mol obtained central unable bind alter soluble levels contrast observed solanezumab preferentially recognizes central epitope central peptide bound crenezumab yielded calculated binding free energy free energy bound n-terminal central peptides much smaller terminal epitope sdhrfead aligned original central epitope site anti-ağ›½ğ›½ antibody noted solanezumab binds central gantenerumab. original binding pose central peptide bound crenezumab figure compared initial binding pose central peptide considerably bind n-terminal peptide alternate conformation. sites examined usually higher transposed peptide bound crenezumab. available table percent occupancy central peptide bound n-terminal peptide bound. figure percent occupancy central bound. addition percent occupancy central peptide bound actually increased n-terminal peptide central peptide bound drops n-terminal peptide bound. improving binding affinity pe-ağœ·ğœ·âˆ’ calculated mmpbsa binding free energy anti-ağ›½ğ›½ antibody polymorphic strength specificity antibody additional target. promising mutants study pe-ağ›½ğ›½âˆ’ bound anti-protofibril antibody pfa. study peağ›½ğ›½âˆ’ amyloid peptide shown bind less affinity wild type ağ›½ğ›½âˆ’ peptide pe-ağ›½ğ›½âˆ’ still considered dangerous prominent presence alzheimerâ€™s plaques mutant antibody bind mutant first preliminary simulation bound pe-ağ›½ğ›½âˆ’ compared simulation bound ağ›½ğ›½âˆ’ used previously method validation. particular interest simulation ağ›½ğ›½âˆ’ mutations stabilized bound structure. calculated binding free energy pe-ağ›½ğ›½âˆ’ free energy kcal/mol calculated pe-ağ›½ğ›½âˆ’ bound wildtype structure. given rather large changes binding pose affinity pe-ağ›½ğ›½âˆ’ peptide binding original wild type ağ›½ğ›½âˆ’ ağ›½ğ›½âˆ’ peptides successful mutant binding high affinity multiple species. therefore also examined simulations calculated mmpbsa binding free energies ağ›½ğ›½âˆ’ ağ›½ğ›½âˆ’ bound destabilized binding ağ›½ğ›½âˆ’ peptide calculated binding free energy ağ›½ğ›½âˆ’ interfered binding alanine present ağ›½ğ›½âˆ’ also compensating ağ›½ğ›½âˆ’ ağ›½ğ›½âˆ’ pe-ağ›½ğ›½âˆ’ species mutants generally improved affinity various species albeit modest sacrifice affinity ağ›½ğ›½âˆ’. practice compromise binding species instead cocktail similar antibodies used target various species associated stronger binding anti-ağ›½ğ›½ antibodies presence important polymorphic forms bind antibody drug candidate high affinity primary target decreasing effectiveness. modify improve current anti-ağ›½ğ›½ antibody drugs already undergone clinical trials anti-ağ›½ğ›½ antibodies using fragment-based docking full molecular dynamics simulations effective study binding properties anti-ağ›½ğ›½ antibodies whose crystal structures amino acid residues unbiased fashion surface anti-ağ›½ğ›½ antibodies probe data indicates crenezumab bind n-terminal central epitopes reported ability bind oligomeric fibril species factor epitope insoluble amyloid plaques believed n-terminal bind soluble monomers using central epitope fibril structures crenezumab ultsch suggested fibril species defects expose central epitope along fiber axis allow crenezumab bind locations. recently pointed crenezumab recognize epitope also cross binding occurred assumption necessarily hold responsible cross binding. interesting feature epitope contains improve binding affinity towards pe-ağ›½ğ›½ species ağ›½ğ›½. given high conformational flexibility peptide antibody itself predicting useful mutations static", "year": "2018"}